Satigrel, a new antiplatelet agent, inhibits platelet accumulation in prosthetic arterial grafts

American Journal of Surgery

Volumn 175, Issue 1, 1998, Pages 56-60

  Esato, Kensuke ^a   Kubo, Yoshihiko ^b   Yasuda, Keishu ^c   Shigematsu, Hiroshi ^d   Iwai, Takehisa ^e   Ishimaru, Shin ^f   Uchida, Hatsuzo ^g   Ishii, Katsumi ^h  

^a YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b ASAHIKAWA MEDICAL COLLEGE   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^f TOKYO MEDICAL UNIVERSITY   (Japan)

^g OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^h KITASATO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; DACRON; NEW DRUG; SATIGREL; THROMBOCYTE IN 111;

ADULT; AGED; AORTOFEMORAL BYPASS; ARTERY RECONSTRUCTION; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED STUDY; DACRON VASCULAR PROSTHESIS; FEMORAL ARTERY; GRAFT OCCLUSION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEG REVASCULARIZATION; MALE; ORAL DRUG ADMINISTRATION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCINTIGRAPHY; TABLET; THROMBOCYTE AGGREGATION INHIBITION;

AGED; ARTERIOSCLEROSIS OBLITERANS; BLOOD PLATELETS; BLOOD VESSEL PROSTHESIS; DATA INTERPRETATION, STATISTICAL; FATTY ACIDS, MONOUNSATURATED; HUMANS; INDIUM RADIOISOTOPES; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; POLYETHYLENE TEREPHTHALATES; PROSTHESIS FAILURE; RADIONUCLIDE IMAGING; TIME FACTORS;

EID: 0031984091     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(97)00224-9     Document Type: Article

References (14)

1. 1. Ross R. The pathogenesis of atherosclerosis. NEJM. 1986;314: 488-500.
2. 2. Freeman MB, Sicard GA, Valentin LI, et al. The association of in vitro arachidonic acid responsiveness and plasma thromboxane levels with early platelet deposition on the luminal surface of small-diameter grafts. J Vasc Surg. 1988;7:554-561.
3. 1 infusion on canine arterial graft patency. Arch Surg. 1986;121:760-764.
4. 4. Born GVR, Cross MJ. The aggregation of blood platelets. J Physiol (Lond). 1963;168:178-195.
5. 5. Rutherford RB, Nishikimi N. Graft thrombosis and thromboembolic complications. In: Rutherford RB, ed. Vascular Surgery. Philadelphia: WB Saunders; 1989:501-510.
6. 6. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-II: maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ. 1994;308: 159-168.
7. 7. Fujimori T, Harada K, Saeki T, et al. E5510, a novel antiplatelet drug with multiple modes of action. Cardiovasc Drug Reviews. 1991;9:264-284.
8. 8. Tsunoo M, Ikeda Y, Horai Y, et al. Phase I studies of E5510, a new antiplatelet agent, in healthy male subjects. Single and multiple dose studies. Kiso to Rinsyo (Japanese). 1995;29:126-151.
9. 9. The Japanese E5510 TIA Study-1 (JETS-1) Group. A randomized trial of E5510 versus aspirin in patients with transient ischemic attacks. Angiology. 1995;46:999-1008.
10. 10. Nomoto K, Saeki T, Kogushi M, et al. Inhibitory effects of a novel antiplatelet agent, E5510, on collagen-induced platelet-derived growth factor release and aggregation of human platelets in vitro. Japan J Pharmacol. 1993;61:7-12.
11. 11. Fujioka K, Esato K, Furutani A, et al. Effect of E5510 on anastomotic intimal hyperplasia and platelet aggregation in dogs. J Cardiovasc Pharmacol. 1996;27:824-830.
12. 12. Thakur ML, Welch MJ, Joist JH, Coleman RE. Indium-111-labeled platelets: studies on preparation and evaluation of in vitro and in vivo functions. Thromb Res. 1976;9:345-357.
13. 13. Goldman M, Norcott HC, Hawker RJ, et al. Femoropopliteal bypass grafts-an isotope technique allowing in vivo comparison of thrombogenicity. Br J Surg. 1982;69:380-382.
14. 14. Stratton JR, Ritchie JL. Reduction of indium-111 platelet deposition on dacron vascular grafts in humans by aspirin plus dipyridamole. Circulation. 1986;73:325-330.